EXODOTS for diagnostic evaluation and monitoring of Alzheimer's disease

项目概要/摘要 阿尔茨海默病（Alzheimer's disease，AD）是最常见的神经退行性疾病。尽管疾病很严重， 由于神经心理学测试的低准确性或高成本，AD的早期诊断仍然具有挑战性， 神经成像开发一种准确和具有成本效益的非侵入性筛查技术， 在不可逆的脑损伤或智力衰退之前监测AD是至关重要的。WellSIM建议开发和 验证用于检测和定量AD的高灵敏度免疫荧光测定法（称为EXODOTS） 以高准确度、高速度和低成本从循环细胞外囊泡（EV）中提取核心生物标志物。这 基于血液的检测将有助于在初级保健环境中对AD患者进行微创评估， 持续监测疾病进展。

PROJECT SUMMARY / ABSTRACT Alzheimer's disease (AD) is the most widespread neurodegenerative disorder. Despite the severity of the disease, early diagnosis of AD is still challenging due to the low accuracy or high cost of neuropsychological tests and neuroimaging. Development of an accurate and cost-effective technology for non-invasive screening and monitoring of AD before irreversible brain damage or mental decline is critical. WellSIM proposes to develop and validate a highly sensitive immunofluorescence assay, termed EXODOTS, for detection and quantification of AD core biomarkers from circulating extracellular vesicles (EV) with high accuracy, high speed, and low cost. This blood-based assay will facilitate minimally invasive assessment of AD patients in primary care settings and continuous monitoring of disease progression.